Investing.com - Financial Markets Worldwide
🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial

Published 10/07/2024, 10:05 pm
Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial

Highlights

  • The first patient in the Phase 1 bile tract cancer trial has been dosed.
  • The trial is expected to enrol 10 patients with bile tract cancer.
  • The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escalation trial is open and enrolling.

Imugene Limited (ASX: IMU) has dosed the first patient in its Phase 1 bile tract cancer (cholangiocarcinoma) trial. This trial marks the expansion of the MAST (Metastatic Advanced Solid Tumours) Phase 1 study, following promising responses in gastrointestinal cancers, particularly bile tract cancer, using VAXINIA, an oncolytic virus CF33.

The trial is being conducted at St. Vincent’s Hospital and aims to enrol 10 patients with bile tract cancer.

Triggered by the update, IMU shares jumped 7.8% to trade at AU$0.055 apiece at the time of writing on 10 July 2024.

Read more on Kalkine Media

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.